New England Biolabs
A life-science research company supplying restriction enzymes, molecular biology reagents, sequencing tools, and genome-engineering products.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
New England Biolabs (NEB) is an American life-science tools company headquartered in Ipswich, Massachusetts. It develops and supplies recombinant and native enzymes, nucleic-acid purification products, molecular biology reagents, cloning systems, PCR and reverse-transcription reagents, next-generation sequencing workflows, and genome-editing tools. The company is especially associated with restriction enzymes, which scientists use to cut DNA at defined recognition sites for cloning, mapping, library preparation, and other forms of genomic research. NEB was founded in 1974 by Donald “Don” Comb, a Harvard Medical School professor, as a cooperative laboratory of experienced scientists. The organization initially focused on producing restriction enzymes at commercial scale, helping establish a specialist supplier for researchers who needed reliable, well-characterized enzymes rather than general laboratory chemicals. Comb remained closely involved for decades, serving as chief executive from the company’s founding until 2005. He then returned to research while continuing as chairman of the board. James Ellard became chief executive in 2005, and Salvatore “Sal” Russello succeeded Ellard in 2022. Comb died in 2020 at the age of 93. The company’s portfolio has expanded well beyond its original restriction-enzyme focus. NEB produces hundreds of recombinant and native restriction enzymes, as well as nicking enzymes and DNA methylases. Its broader molecular biology range includes high-fidelity DNA polymerases, PCR and RT-qPCR systems, DNA assembly and cloning products, RNA and DNA purification kits, nucleic-acid modification reagents, and kits for next-generation sequencing. The NEBuilder and Gibson Assembly families support multi-fragment DNA construction and synthetic-biology workflows, while the Monarch range provides DNA and RNA purification products. The NEBNext portfolio addresses library preparation, RNA depletion, targeted genotyping, and other sequencing applications. NEB also participates in genome editing, proteomics, DNA sequencing, drug-discovery research, molecular biology, and parasitology. In 2020 it entered an agreement with ERS Genomics to sell CRISPR/Cas9 tools and reagents. The company has supported infectious-disease research as well. During the COVID-19 pandemic, its reagents and protocols were used in nucleic-acid extraction and loop-mediated isothermal amplification workflows, and the company launched sequencing kits in 2021 to support SARS-CoV-2 surveillance. A Color Health SARS-CoV-2 RT-LAMP diagnostic assay using NEB reagents received emergency-use authorization in 2021. Research infrastructure is a notable part of the brand. NEB operates REBASE, a restriction-enzyme and DNA-modification database, and provides free access to InBase, an intein database, and Polbase, a polymerase database established in 2011. These resources reinforce the company’s position as a technically oriented supplier rather than simply a catalog vendor. NEB has also participated in scientific and industry partnerships, including the Ocean Genome Legacy initiative, the Human Glycome Project, Bioz product-application information, and distribution and sustainability collaborations. The company maintains subsidiaries in several major markets and uses distributors elsewhere. Its current Ipswich headquarters was developed beginning in 2000 and completed in 2005. NEB also established a GMP manufacturing capability near its headquarters: the Rowley Cleanroom Manufacturing Facility was completed in 2018 and produces GMP-grade materials. Company culture emphasizes direct technical engagement, with scientists and some executives expected to spend time answering customer-support questions. This model, combined with extensive technical documentation and research databases, supports NEB’s positioning as a high-quality, research-driven provider for academic, biotechnology, pharmaceutical, agricultural, and diagnostic laboratories.
History
New England Biolabs was established in 1974 by Donald “Don” Comb, a Harvard Medical School professor, as a cooperative laboratory formed around experienced molecular biologists. Its earliest commercial focus was the production of restriction enzymes. These enzymes became essential tools for recombinant-DNA work because they cut DNA at defined sequences, allowing researchers to build, analyze, and manipulate genetic constructs. NEB developed a reputation for supplying carefully characterized enzymes and for linking commercial products with scientific research. Comb led the company as chief executive from its founding until 2005. During that period NEB expanded from restriction enzymes into a wider range of recombinant and native enzymes, including DNA-modification enzymes, nicking enzymes, and DNA methylases. The organization also built capabilities in DNA sequencing, proteomics, drug discovery, molecular biology, and parasitology. Its approach remained unusually research-centered for a commercial reagent supplier: scientists were involved in customer technical support, and the company invested in freely accessible databases that helped researchers select and understand enzymes. NEB’s present headquarters in Ipswich, Massachusetts, began development in 2000 and was completed in 2005. In that same year, James Ellard replaced Comb as chief executive, while Comb continued as chairman and returned more fully to research. Comb died in October 2020 at the age of 93. Ellard later stepped down as CEO in 2022 and remained chairman, with Salvatore “Sal” Russello taking over as chief executive. During the 2010s, NEB broadened its workflow coverage. The company introduced the Luna qPCR and RT-qPCR families in 2017 and expanded its NEBNext sequencing portfolio with the Ultra II FS DNA library-preparation kit. It launched the Monarch Genomic DNA Purification Kit in 2019 and added RNA-depletion and targeted-genotyping solutions to address increasingly specialized sequencing workflows. NEBuilder HiFi DNA Assembly and Gibson Assembly products extended the company’s role into synthetic biology and multi-fragment cloning. NEB also developed research infrastructure beyond its product catalog. REBASE provides information on restriction enzymes and related DNA-modification systems. Polbase, founded in 2011, focuses on DNA polymerases, while InBase covers inteins and includes an intein registry. These resources give researchers free access to technical information and strengthen NEB’s identity as a scientific institution as well as a manufacturer. The company expanded its international presence through subsidiaries in Canada, China, France, Germany, Japan, Singapore, the United Kingdom, and Australia, together with distributors in additional regions. It also developed partnerships involving genome engineering, scientific data, distribution, sustainability, and glycomics. NEB co-founded the Ocean Genome Legacy initiative in 2001, although that collection later moved from the NEB campus to Northeastern University. In 2019, NEB joined Waters and Genos in the Human Glycome Project and partnered with Bioz to provide customers with examples of real-world product use. Manufacturing infrastructure became another strategic priority. NEB committed in 2015 to a GMP facility near Ipswich, and the 40,000-square-foot Rowley Cleanroom Manufacturing Facility was completed in 2018. The facility produces GMP-grade materials and includes a 10,000-square-foot mechanical mezzanine. The company also received approximately $1.7 million in Small Business Innovation Research grants between 2009 and 2013 for research activities. The COVID-19 pandemic highlighted NEB’s role in infectious-disease workflows. Its LAMP materials, RNA purification products, and supplementary sample-processing protocols were used in assay development. In 2021, NEB introduced sequencing kits based on ARTIC Network methods to support SARS-CoV-2 surveillance. A Color Health RT-LAMP diagnostic assay using NEB reagents subsequently received emergency-use authorization. NEB remains an active supplier of molecular biology and life-science research tools, with restriction enzymes at the core of a portfolio that now spans cloning, sequencing, purification, genome editing, and specialized manufacturing.
- 2022
CEO succession
[1]Salvatore Russello succeeded James Ellard as chief executive, while Ellard remained chairman.
- 2021
SARS-CoV-2 sequencing products introduced
[1]NEB launched three sequencing kits based on ARTIC Network methods for SARS-CoV-2 monitoring.
- 2020
CRISPR/Cas9 commercial agreement
[1]NEB entered an agreement with ERS Genomics to sell CRISPR/Cas9 tools and reagents.
- 2019
Expansion into RNA depletion and genotyping
[1]NEB introduced RNA-depletion products and announced a targeted, automatable genotyping solution.
- 2018
Rowley Cleanroom Manufacturing Facility completed
[1]The 40,000-square-foot Rowley facility was completed to manufacture GMP-grade products.
- 2015
GMP manufacturing investment announced
[1]NEB committed to establishing a GMP manufacturing facility near its Massachusetts headquarters.
- 2011
Polbase established
[1]NEB established Polbase, a free online resource focused on DNA polymerases.
- 2005
Leadership transition and headquarters completion
[1]The Ipswich headquarters was completed, James Ellard became CEO, and Donald Comb moved from executive management back toward research while remaining chairman.
- 2001
Ocean Genome Legacy co-founded
[1]NEB co-founded the Ocean Genome Legacy initiative to preserve and make marine biological samples available for research.
- 2000
Ipswich headquarters development begins
[1]Construction and development began on the company’s current headquarters campus in Ipswich, Massachusetts.
Products and positioning
A research-driven, high-quality supplier of molecular biology enzymes, reagents, databases, and workflow products for life-science laboratories.
DNA-cleaving enzymes · 1974
Restriction enzymes
NEB’s historic core offering consists of recombinant and native restriction enzymes used to cut DNA at defined recognition sites. The range supports cloning, plasmid construction, genomic analysis, DNA mapping, and sequencing workflows. NEB also supplies related nicking enzymes and DNA methylases, making the portfolio useful for both routine molecular biology and specialized DNA-modification research.
PCR reagent
Q5 High-Fidelity DNA Polymerase
Q5 is a high-fidelity DNA polymerase used for amplification where sequence accuracy is important. It is positioned for cloning, mutagenesis, difficult templates, and other applications requiring dependable amplification performance. The product represents NEB’s expansion from restriction enzymes into broader PCR and DNA-engineering workflows.
Quantitative PCR · 2017
Luna qPCR and RT-qPCR kits
Introduced in 2017, Luna kits support quantitative measurement of DNA and RNA. The range includes workflows in which RNA is first converted to complementary DNA and then quantified, making the products applicable to gene-expression analysis, assay development, and molecular detection research.
DNA assembly and cloning
NEBuilder HiFi DNA Assembly
NEBuilder HiFi DNA Assembly enables one-step joining of multiple DNA fragments. The enzyme mix is designed for assemblies ranging from small constructs to considerably larger fragments, supporting synthetic biology, plasmid construction, pathway engineering, and other cloning applications.
DNA assembly and cloning
Gibson Assembly Master Mix
Gibson Assembly Master Mix supports seamless combination of overlapping DNA fragments in a single reaction. It is used for constructing recombinant plasmids, assembling synthetic sequences, and building larger genetic designs without relying exclusively on conventional restriction-enzyme cloning.
Next-generation sequencing · 2017
NEBNext products
The NEBNext family supports next-generation sequencing workflows, including DNA library preparation, RNA depletion, and targeted genotyping. Products such as the Ultra II FS DNA library-preparation kit and depletion kits are intended to improve preparation of samples for sequencing and reduce unwanted nucleic-acid species.
DNA and RNA purification · 2019
Monarch nucleic-acid purification
Monarch products purify genomic DNA, RNA, and other nucleic-acid preparations for downstream molecular biology. The Genomic DNA Purification Kit, introduced in 2019, was designed to reduce RNA carryover and support high-yield recovery of large DNA fragments. The products are used in research involving sequencing, genetics, microbiology, and assay development.
Genome editing · 2020
CRISPR/Cas9 tools and reagents
Following its 2020 agreement with ERS Genomics, NEB added CRISPR/Cas9 tools and reagents to its commercial portfolio. These products support research applications involving targeted genome modification, gene knockout, and engineered biological systems.
GMP manufacturing · 2018
GMP-grade molecular biology products
NEB manufactures GMP-grade products at its Rowley Cleanroom Manufacturing Facility in Massachusetts. The site was completed in 2018 and provides controlled manufacturing capacity for products intended for applications requiring a higher level of process and quality-system support.
Marketing campaigns
- 2021SARS-CoV-2 genomic surveillance support
United States · Worldwide
NEB launched three next-generation sequencing kits based on ARTIC Network protocols to help laboratories monitor SARS-CoV-2 transmission and genetic evolution.
Outcome. The products extended NEB’s pandemic response from diagnostic assay development into sequencing-based surveillance.
- 2020COVID-19 LAMP and sample-processing support
United States · Worldwide
NEB developed research-use colorimetric LAMP materials and supplied RNA purification reagents and supplementary protocols relevant to saliva, buccal-swab, and nasopharyngeal samples during the COVID-19 response.
Outcome. The materials supported development of rapid nucleic-acid detection workflows and the broader use of NEB reagents in SARS-CoV-2 assay development.
Brand decisions
2020
CRISPR/Cas9 commercial agreement with ERS GenomicsM&ABackground
Genome-editing researchers required accessible commercial reagents for CRISPR/Cas9 experiments.
Action taken
NEB signed an agreement granting it rights to sell ERS Genomics CRISPR/Cas9 tools and reagents.
Aftermath
NEB added genome-editing products to its molecular biology and synthetic-biology portfolio.
2019
Launch of RNA-depletion and targeted-genotyping productsProduct launchBackground
Sequencing workflows often require removal of abundant RNA species or streamlined targeted genotyping.
Action taken
NEB introduced Globin and rRNA Depletion kits, a bacterial rRNA Depletion kit, and the NEBNext Direct Genotyping Solution.
Aftermath
The portfolio addressed transcriptome analysis and automatable genotyping applications, including agricultural biotechnology.
2017
Launch of Luna qPCR and RT-qPCR kitsProduct launchBackground
Researchers needed integrated reagents for quantitative DNA and RNA measurement.
Action taken
NEB introduced Luna universal qPCR and RT-qPCR kits.
Aftermath
The launch broadened NEB’s PCR offering beyond its established enzyme portfolio.
2017
Expansion of NEBNext sequencing productsProduct launchBackground
Demand for reliable next-generation sequencing library preparation created opportunities for specialized reagent suppliers.
Action taken
NEB released the NEBNext Ultra II FS DNA library-preparation kit.
Aftermath
The product strengthened NEB’s presence in sequencing sample-preparation workflows.
2015
Investment in GMP manufacturingStrategyBackground
NEB sought additional manufacturing capability for products requiring GMP-oriented production standards.
Action taken
The company committed to constructing a cleanroom manufacturing facility near its Ipswich headquarters.
Aftermath
The Rowley Cleanroom Manufacturing Facility was completed in 2018 and produces GMP-grade products.
Recent events
NEB releases LyoPrime Luna RT-qPCR Mix[3]
New England Biolabs announced the release of its first lyophilized product manufactured by Fluorogenics: LyoPrime Luna Probe One-Step RT-qPCR Mix with UDG.
New England Biolabs releases updated WarmStart LAMP products[4]
Reported:
New England Biolabs announced the release of two WarmStart LAMP products: the Multi-Purpose LAMP/RT-LAMP 2X Master Mix (with UDG) and the Fluorescent LAMP/RT-LAMP Kit (with UDG).
New England Biolabs launches Primer Monitor Tool[5]
Reported:
New England Biolabs announced the launch of a web-based tool for monitoring SARS-CoV-2 variants and their potential impact on COVID-19 diagnostic tests.
New England Biolabs releases ARTIC SARS-CoV-2 sequencing kits[6]
Reported:
New England Biolabs released three NEBNext ARTIC SARS-CoV-2 kits for multiplexed amplicon-based sequencing of viral RNA, with options for Illumina and Oxford Nanopore Technologies platforms.
Sources6 sources
- 1New England Biolabsen.wikipedia.org
- 2New England Biolabs official websiteneb.com
- 3NEB 发布 LyoPrime Luna RT-qPCR Mixbiospectrumindia.com
- 4New England Biolabs 推出更新版 WarmStart LAMP 产品prnewswire.com
- 5New England Biolabs推出Primer Monitor Toolprnewswire.com
- 6New England Biolabs 发布 ARTIC SARS-CoV-2 测序试剂盒prnewswire.com
Cite this profile: Cite the canonical profile. /brand-wiki/new-england-biolabs · Editorial policy · How profiles are compiled